Tao Sun

3.8k total citations · 2 hit papers
92 papers, 1.4k citations indexed

About

Tao Sun is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Tao Sun has authored 92 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Oncology, 44 papers in Pulmonary and Respiratory Medicine and 19 papers in Molecular Biology. Recurrent topics in Tao Sun's work include Advanced Breast Cancer Therapies (31 papers), HER2/EGFR in Cancer Research (29 papers) and Cancer Treatment and Pharmacology (22 papers). Tao Sun is often cited by papers focused on Advanced Breast Cancer Therapies (31 papers), HER2/EGFR in Cancer Research (29 papers) and Cancer Treatment and Pharmacology (22 papers). Tao Sun collaborates with scholars based in China, United States and United Kingdom. Tao Sun's co-authors include Junnan Xu, Bruce Neal, Ngozi Erondu, Qiang Li, Dick de Zeeuw, David R. Matthews, Greg Fulcher, Wayne Shaw, Vlado Perkovic and Kenneth W. Mahaffey and has published in prestigious journals such as Circulation, Nature Medicine and Nature Communications.

In The Last Decade

Tao Sun

81 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events

2017 375 citations Kenneth W. Mahaffey, Bruce Neal et al. Circulation profile →
Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial

2025 16 citations Yongmei Yin, Ying Fan et al. Nature Medicine profile →

Peers

Countries citing papers authored by Tao Sun

Since Specialization

Citations

This map shows the geographic impact of Tao Sun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tao Sun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tao Sun more than expected).

Fields of papers citing papers by Tao Sun

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tao Sun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tao Sun. The network helps show where Tao Sun may publish in the future.

Co-authorship network of co-authors of Tao Sun

This figure shows the co-authorship network connecting the top 25 collaborators of Tao Sun. A scholar is included among the top collaborators of Tao Sun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tao Sun. Tao Sun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial breakdown → 2025 ·Nature Medicine ·Yongmei Yin, Ying Fan, (unknown), (unknown), Xiaojia Wang, Wěi Li, Man Li, Xi Yan, Shusen Wang, Tao Sun, (unknown), (unknown), Zhongsheng Tong, (unknown), (unknown), Xiaoping Jin, (unknown), (unknown), Binghe Xu	16
2	Recent advances in copper sulfide nanoparticles for cancer diagnosis and therapy 2025 ·Materials Today Bio ·(unknown), (unknown), Zhangrong Lou, Junnan Xu, Yiwen Ma, Xiaorui Li, Qiang Liu, Tao Sun	0
3	Microstructural evolution and mechanical properties of snow under compression 2025 ·Construction and Building Materials ·(unknown), Hao Zheng, (unknown), Tao Sun, (unknown), (unknown)	5
4	Advances in smart nanotechnology-supported photodynamic therapy for cancer 2024 ·Cell Death Discovery ·Guangyao Li, Cong Wang, Binghui Jin, Tao Sun, (unknown), (unknown), Zhe Fan	35
5	Intratumoral and fecal microbiota reveals microbial markers associated with gastric carcinogenesis 2024 ·Frontiers in Cellular and Infection Microbiology ·Yiwen Wang, (unknown), (unknown), Mengzhen Han, Xiaolin Liu, (unknown), Yuesheng Dong, Tao Sun, Junnan Xu	10
6	ACE-Breast-02: A pivotal phase II/III trial of ARX788, a novel anti-HER2 antibody-drug conjugate (ADC), versus lapatinib plus capecitabine for HER2+ advanced breast cancer (ABC). 2024 ·Journal of Clinical Oncology ·Xichun Hu, Leiping Wang, Jian Zhang, Qingyuan Zhang, Quchang Ouyang, Xiaojia Wang, Wěi Li, Weimin Xie, Zhongsheng Tong, Faliang Xu, (unknown), (unknown), Tao Sun	7
7	A phase Ib study of PI3Kα inhibitor risovalisib mesylate in combination with fulvestrant in patients with PIK3CA-mutated, HR+/HER2- advanced breast cancer. 2024 ·Journal of Clinical Oncology ·Jiong Wu, Jian Zhang, Man Li, Li Cai, Tao Sun, Quchang Ouyang, Yanchun Meng, Yehui Shi, Chuan Wang, Qiang Liu, Yongkui Lu, Yongmei Yin, Qianjun Chen, Lilin Chen, Haitao Wang, Jiuwei Cui, Ning Liao, Shubin Wang, Yi Tu, Min Yan	1
8	Exploring gut microbiome markers in predicting efficacy of immunotherapy against lung cancer. 2024 ·Journal of Clinical Oncology ·(unknown), Junnan Xu, Tao Sun, Yuhang Zhou, Yun Feng, Han Li, Xiaolin Liu	0
9	Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer: a long-term safety and overall survival update from the randomised, double-blind, placebo-controlled, phase 3 trial 2023 ·PubMed ·Qingyuan Zhang, Wei Li, Xichun Hu, Tao Sun, Shude Cui, Shusen Wang, Quchang Ouyang, Yongmei Yin, Cuizhi Geng, Zhongsheng Tong, Ying Cheng, Zhiqiang Ning, Zefei Jiang	4
10	Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial 2023 ·Cell Research ·Yin Liu, Xiu-Zhi Zhu, Yi Xiao, Song‐Yang Wu, Wen‐Jia Zuo, Qiang Yu, A‐Yong Cao, Junjie Li, Ke‐Da Yu, Guang‐Yu Liu, Jiong Wu, Tao Sun, Jiuwei Cui, Zheng Lv, Huiping Li, Xiaoyu Zhu, Yi‐Zhou Jiang, Zhonghua Wang, Zhi‐Ming Shao	39
11	Identification of microbial markers associated with lung cancer based on multi‐cohort 16 s rRNA analyses: A systematic review and meta‐analysis 2023 ·Cancer Medicine ·(unknown), Na Wang, Mengzhen Han, Xiaolin Liu, Tao Sun, (unknown)	11
12	A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple‐negative breast cancer who received at least two prior treatments 2023 ·International Journal of Cancer ·Binghe Xu, Fei Ma, Tao Wang, Shusen Wang, Zhongsheng Tong, Wěi Li, Xinhong Wu, Xiaojia Wang, Tao Sun, Yueyin Pan, Herui Yao, Xian Wang, Ting Luo, Jin Yang, Xiaohua Zeng, (unknown), Xiuyu Julie Cong, (unknown)	27
13	N‐((1‐(4‐Fluorophenyl)‐1H‐1,2,3‐triazol‐4‐yl)methyl)‐2‐methylene‐3‐oxo‐olean‐12‐en‐28‐amide Induces Apoptosis in Human Breast Cancer Cells by Stimulating Oxidative Stress and Inhibiting the Notch‐Akt Signaling Pathway 2022 ·Oxidative Medicine and Cellular Longevity ·Xiaorui Li, Shisheng Wang, Ning Deng, (unknown), (unknown), (unknown), Tao Sun	2
14	Major depressive symptoms in breast cancer patients with ovarian function suppression: a cross-sectional study comparing ovarian ablation and gonadotropin-releasing hormone agonists 2021 ·BMC Psychiatry ·(unknown), Junnan Xu, Li Cai, Man Li, Limin Niu, Juan Hu, Tao Sun, Xinyu Zheng	7
15	Does a ketogenic diet as an adjuvant therapy for drug treatment enhance chemotherapy sensitivity and reduce target lesions in patients with locally recurrent or metastatic Her-2-negative breast cancer? Study protocol for a randomized controlled trial 2020 ·Trials ·Yan Wang, (unknown), Lei Jiang, (unknown), Er‐Bo Ying, Hui Cao, Xiangyu Guo, Tao Sun	17
16	Autophagic Vacuole Secretion Triggered by Chidamide Participates in TRAIL Apoptosis Effect in Breast Cancer Cells 2020 ·Current Pharmaceutical Design ·Weiqiang Zhou, (unknown), Junnan Xu, Tao Sun, (unknown)	7
17	Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study 2020 ·Breast Cancer Research and Treatment ·Binghe Xu, Wei Li, Qingyuan Zhang, Zhimin Shao, Qiao Li, Xiaojia Wang, Huiping Li, Tao Sun, Yongmei Yin, Hong Zheng, Jifeng Feng, Hong Zhang, Guiyuan Lei, Eleonora Restuccia	29
18	<p>Identification of Aurora Kinase A as a Biomarker for Prognosis in Obesity Patients with Early Breast Cancer</p> 2020 ·OncoTargets and Therapy ·(unknown), (unknown), Junnan Xu, Tao Sun, Xinyu Zheng	7
19	Germline mutation landscape of Chinese patients with familial breast/ovarian cancer in a panel of 22 susceptibility genes 2019 ·Cancer Medicine ·Jiayu Wang, (unknown), Yujian Shi, (unknown), Tao Sun, Lili Tang, Qing Lü, (unknown), Ning Liao, Feng Jin, (unknown), Tao Huang, Jun Qian, Danmei Pang, Shusen Wang, (unknown), Xinhong Wu, Ying Lin, Haiyan Qin, Binghe Xu	17
20	Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events breakdown → 2017 ·Circulation ·Kenneth W. Mahaffey, Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Elisa Fabbrini, Tao Sun, Qiang Li, Mehul Desai, David R. Matthews	375

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact